Innate gains from damaging departure at pharma major

20 December 2016

The share price of AstraZeneca (LSE: AZN) has suffered a further hit this week with the news that it is to lose its head of oncology.

Mondher Mahjoubi is leaving the Anglo-Swedish pharma major to become chief executive of France-based Innate Pharma (Euronext Paris: IPH), the innate immunity company developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases.

"After 17 years building Innate Pharma, I am convinced that now is the time for new leadership to take the company to the next level"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK